Premium
Neoadjuvant therapy for esophageal cancer: Who, when, and what?
Author(s) -
Greally Megan,
Ilson David H.
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31768
Subject(s) - medicine , docetaxel , esophageal cancer , oxaliplatin , neoadjuvant therapy , oncology , perioperative , carcinoma , lymph node , cancer , surgery , colorectal cancer , breast cancer
The perioperative combination of 5‐fluorouracil, oxaliplatin, and docetaxel is a new standard treatment in patients with esophageal carcinoma. However, chemoradiation results in higher R0 surgical resection rates, pathologic complete response, and negative lymph node status. The identification of molecular subsets may influence the design of future studies and guide drug development.